Skip to main content
Premium Trial:

Request an Annual Quote

Kenneth Buechler, Dirk van den Boom

Sequenom's board of directors has elected Kenneth Buechler its chairman, effective April 1. He succeeds Harry Hixson, who is retiring from the position after 11 years. Also, Dirk van den Boom was elected as a director, effective April 1.

Buechler has been on Sequenom's board since late 2009 and was previously president and CSO of Biosite, which he co-founded. Before that he was a senior research scientist for the diagnostics R&D group at Hybritech. 

Van den Boom is currently executive vice president and chief scientific and strategy officer at Sequenom. He will serve on the board's science committee.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.